BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 20820873)

  • 1. Expression of O⁶-methylguanine-DNA methyltransferase in childhood medulloblastoma.
    Faoro D; von Bueren AO; Shalaby T; Sciuscio D; Hürlimann ML; Arnold L; Gerber NU; Haybaeck J; Mittelbronn M; Rutkowski S; Hegi M; Grotzer MA
    J Neurooncol; 2011 May; 103(1):59-69. PubMed ID: 20820873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma.
    Tuominen R; Jewell R; van den Oord JJ; Wolter P; Stierner U; Lindholm C; Hertzman Johansson C; Lindén D; Johansson H; Frostvik Stolt M; Walker C; Snowden H; Newton-Bishop J; Hansson J; Egyházi Brage S
    Int J Cancer; 2015 Jun; 136(12):2844-53. PubMed ID: 25400033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours.
    von Bueren AO; Bacolod MD; Hagel C; Heinimann K; Fedier A; Kordes U; Pietsch T; Koster J; Grotzer MA; Friedman HS; Marra G; Kool M; Rutkowski S
    Br J Cancer; 2012 Oct; 107(8):1399-408. PubMed ID: 22976800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation.
    Kreth S; Thon N; Eigenbrod S; Lutz J; Ledderose C; Egensperger R; Tonn JC; Kretzschmar HA; Hinske LC; Kreth FW
    PLoS One; 2011 Feb; 6(2):e17156. PubMed ID: 21365007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intercellular heterogeneity of expression of the MGMT DNA repair gene in pediatric medulloblastoma.
    Rood BR; Zhang H; Cogen PH
    Neuro Oncol; 2004 Jul; 6(3):200-7. PubMed ID: 15279712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.
    Paz MF; Yaya-Tur R; Rojas-Marcos I; Reynes G; Pollan M; Aguirre-Cruz L; García-Lopez JL; Piquer J; Safont MJ; Balaña C; Sanchez-Cespedes M; García-Villanueva M; Arribas L; Esteller M
    Clin Cancer Res; 2004 Aug; 10(15):4933-8. PubMed ID: 15297393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?
    Tanaka S; Akimoto J; Narita Y; Oka H; Tashiro T
    J Neurosurg; 2014 Oct; 121(4):818-26. PubMed ID: 25105699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RASSF1A promoter is highly methylated in primitive neuroectodermal tumors of the central nervous system.
    Inda MM; Castresana JS
    Neuropathology; 2007 Aug; 27(4):341-6. PubMed ID: 17899687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
    Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
    Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients.
    Sartore-Bianchi A; Pietrantonio F; Amatu A; Milione M; Cassingena A; Ghezzi S; Caporale M; Berenato R; Falcomatà C; Pellegrinelli A; Bardelli A; Nichelatti M; Tosi F; De Braud F; Di Nicolantonio F; Barault L; Siena S
    Eur J Cancer; 2017 Jan; 71():43-50. PubMed ID: 27997874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
    Hegi ME; Diserens AC; Godard S; Dietrich PY; Regli L; Ostermann S; Otten P; Van Melle G; de Tribolet N; Stupp R
    Clin Cancer Res; 2004 Mar; 10(6):1871-4. PubMed ID: 15041700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma.
    Grotzer MA; Hogarty MD; Janss AJ; Liu X; Zhao H; Eggert A; Sutton LN; Rorke LB; Brodeur GM; Phillips PC
    Clin Cancer Res; 2001 Aug; 7(8):2425-33. PubMed ID: 11489822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling.
    Pyko IV; Nakada M; Sabit H; Teng L; Furuyama N; Hayashi Y; Kawakami K; Minamoto T; Fedulau AS; Hamada J
    Carcinogenesis; 2013 Oct; 34(10):2206-17. PubMed ID: 23715499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. O⁶-methylguanine-DNA methyltransferase promoter methylation in 45 primary central nervous system lymphomas: quantitative assessment of methylation and response to temozolomide treatment.
    Adachi J; Mishima K; Wakiya K; Suzuki T; Fukuoka K; Yanagisawa T; Matsutani M; Sasaki A; Nishikawa R
    J Neurooncol; 2012 Mar; 107(1):147-53. PubMed ID: 21968944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of IFN-beta on human glioma cell lines with temozolomide resistance.
    Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E
    Int J Oncol; 2009 Jul; 35(1):139-48. PubMed ID: 19513561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promoter methylation and expression analysis of MGMT in advanced pediatric brain tumors.
    Sardi I; Cetica V; Massimino M; Buccoliero AM; Giunti L; Genitori L; Aricò M
    Oncol Rep; 2009 Oct; 22(4):773-9. PubMed ID: 19724855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07.
    Schraml P; von Teichman A; Mihic-Probst D; Simcock M; Ochsenbein A; Dummer R; Michielin O; Seifert B; Schläppi M; Moch H; von Moos R
    Oncol Rep; 2012 Aug; 28(2):654-8. PubMed ID: 22614944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrent PNET with MGMT methylation responds to temozolomide.
    Oh J; Bilbao JM; Tsao MN; Fazl M; Guiot MC; Del Maestro RF; Perry JR
    Can J Neurol Sci; 2009 Sep; 36(5):654-7. PubMed ID: 19831139
    [No Abstract]   [Full Text] [Related]  

  • 19. [Detection of O6-methylguanine-DNA methyltransferase promoter methylation in chemotherapy for glioma].
    Zheng CQ; Ji SP; Gong F; Li AM; Tai JL; Zhang YP
    Ai Zheng; 2009 Jun; 28(6):575-80. PubMed ID: 19635193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
    Gutenberg A; Bock HC; Brück W; Doerner L; Mehdorn HM; Roggendorf W; Westphal M; Felsberg J; Reifenberger G; Giese A
    Br J Neurosurg; 2013 Dec; 27(6):772-8. PubMed ID: 23662801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.